Core Insights - Bio-Rad Laboratories, Inc. reported first-quarter 2025 adjusted EPS of $2.54, exceeding the Zacks Consensus Estimate of $1.73 by 46.8% and reflecting a 10.9% increase year-over-year [1][2] - The company experienced a revenue decline of 4.2% year-over-year, with Q1 revenues of $585.4 million missing the Zacks Consensus Estimate by 0.05% [3][10] - Bio-Rad lowered its financial guidance for full-year 2025, now expecting non-GAAP currency-neutral revenues to range from a 1.0% decline to 1.5% growth [7][9] Financial Performance - The GAAP EPS was reported at $2.29, a significant decrease from $13.45 a year ago [2] - Gross profit declined by 6.1% to $306 million, with gross margin contracting by 108 basis points to 52.3% [5] - Operating profit fell 46.9% to $23.7 million, with operating margin contracting by 325 basis points to 4% [5][11] Segment Analysis - Life Science segment sales totaled $228.6 million, down 5.4% year-over-year, primarily due to challenges in the academic research market [3][11] - Clinical Diagnostics segment net sales were $356.8 million, down 3.2% year-over-year, attributed to reduced reimbursements for diabetes testing in China [4][11] Cash Flow and Debt - Bio-Rad ended Q1 2025 with cash and cash equivalents of $1.66 billion, remaining flat sequentially [6] - Total debt at the end of 2024 was $1.20 billion, also flat on a sequential basis [6] - Net cash flow from operating activities increased to $129.9 million compared to $69.8 million a year ago [6] Market Reaction - Following the earnings announcement, Bio-Rad's stock rose by 0.2% in after-market trading [2]

Core Viewpoint - Align Technology, Inc. reported better-than-expected earnings for Q1 2025, with adjusted EPS of $2.13, reflecting a 0.5% increase year-over-year, and surpassing the Zacks Consensus Estimate by 7.6% [1]. However, revenues declined 1.8% year-over-year to $979.3 million, impacted by foreign exchange fluctuations [2][10]. Financial Performance - Adjusted EPS for Q1 2025 was $2.13, up 0.5% from the previous year, while GAAP EPS was $1.27, down 8.6% from $1.39 in Q1 2024 [1]. - Total revenues for Q1 2025 were $979.3 million, a decrease of 1.8% year-over-year, but exceeded the Zacks Consensus Estimate by 0.7% [2]. - Gross profit was $680.1 million, down 2.5% year-over-year, with a gross margin of 70%, a contraction of 51 basis points [4]. Segment Performance - The Clear Aligner segment saw revenues decline by 2.5% year-over-year to $796.8 million, affected by a 3.1% unfavorable foreign exchange impact [3]. - Revenues from Imaging Systems & CAD/CAM Services increased by 1.2% to $182.4 million, also facing a 2.8% negative currency impact [3]. Margins and Expenses - Operating income for Q1 2025 was $135.3 million, down 12.2% year-over-year, with an operating margin of 13.8%, a decrease of 164 basis points [4]. - SG&A expenses decreased by 0.9% to $447.6 million, while R&D expenses increased by 5.8% to $97.2 million [4]. Cash Position and Stock Repurchase - At the end of Q1 2025, cash and cash equivalents stood at $873 million, down from $1.04 billion at the end of Q4 2024 [5]. - The company initiated a stock repurchase plan for the remaining $225 million under the previously approved $1 billion program [6]. Guidance - For the full year 2025, Align Technology expects revenue growth between 3.5% to 5.5%, with a Zacks Consensus Estimate of $4.09 billion, indicating a 2.2% year-over-year growth [8]. - For Q2 2025, the company anticipates revenues between $1.05 billion and $1.07 billion, aligning with the Zacks Consensus Estimate of $1.05 billion [9]. Market Position and Growth - Align Technology reported significant milestones, including 280,000 active Invisalign-trained practitioners and 20 million Invisalign patients treated globally [11]. - The Imaging Systems & CAD/CAM Services segment showed strong growth due to improved scanner and wand revenues from leasing rental program upgrades [11].

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

Core Viewpoint - Chemed Corporation reported strong first-quarter 2025 earnings and revenue growth, but faced stock price decline due to concerns over gross margin contraction and Roto-Rooter segment performance [1][2][14]. Financial Performance - Adjusted EPS for Q1 2025 was $5.63, an increase of 8.3% year over year, surpassing the Zacks Consensus Estimate by 0.5% [1] - GAAP EPS was $4.86, reflecting a 14.6% increase from the previous year [1] - Revenues for the quarter reached $646.9 million, up 9.8% year over year, exceeding the Zacks Consensus Estimate by 1.7% [2] Segment Performance - VITAS segment reported net patient revenues of $407.4 million, a 15.1% increase year over year, driven by an 11.9% rise in days-of-care and a 3.2% increase in Medicare reimbursement rates [4] - Roto-Rooter segment generated sales of $239.5 million, a 1.8% year-over-year increase, with commercial revenues up 7.3% [6] - Roto-Rooter residential revenues decreased by 1.7% year over year, with specific declines in drain cleaning and plumbing services [7] Margin and Expense Analysis - Gross profit increased by 6% year over year to $216.4 million, but gross margin contracted by 119 basis points to 33.5% due to rising service costs [8] - SG&A expenses decreased by 8.9% year over year to $105.6 million, while adjusted operating profit rose by 25.6% to $110.8 million [8] Liquidity and Capital Structure - As of the end of Q1 2025, the company had cash and cash equivalents of $173.9 million, down from $178.4 million at the end of Q4 2024, with no current or long-term debt [9][10] - Net cash provided by operating activities was $32.7 million, compared to $84.5 million in the same period last year [10] Shareholder Returns and Guidance - The company repurchased 50,000 shares for $29.8 million, with approximately $225.6 million remaining under its share repurchase authorization [11] - For 2025, Chemed expects VITAS revenues to grow by 10.5% to 11.3%, while Roto-Rooter is forecasted to grow by 2.4% to 3.0% [12] - Adjusted EPS guidance for 2025 is set between $24.95 and $25.45, indicating an 8.8% growth over 2024 [13]

Core Insights - ResMed Inc. reported adjusted earnings per share (EPS) of $2.37 for Q3 fiscal 2025, reflecting an 11.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 0.4% [1] - The company's revenues for the same quarter reached $1.29 billion, marking a 7.5% year-over-year growth and exceeding the Zacks Consensus Estimate by 0.5% [3] Financial Performance - Adjusted gross profit increased by 10.5% to $773.8 million, with an adjusted gross margin of 59.9%, up 138 basis points year over year [9] - Selling, general and administrative expenses rose 6.7% to $245.3 million, while research and development expenses increased by 8.9% to $83.9 million [10] - Adjusted operating income was $444.6 million, up 13% from the previous year, with an adjusted operating margin of 34.4%, expanding by 154 basis points [10] Revenue Breakdown - The Sleep and Breathing Health segment generated revenues of $1.13 billion, an 8% increase year over year, with global device sales totaling $676.2 million, up 6% [6] - In the Residential Care Software segment, revenues grew 9% year over year to $161.2 million, slightly below projections [8] Market Reaction - Following the earnings announcement, ResMed's shares rose by 2.6% in after-market trading [2] Strategic Developments - The company launched the NightOwl, an FDA-cleared home sleep apnea test, and introduced a brand evolution to unify its brand portfolio [15]

Core Insights - Thermo Fisher Scientific Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of $5.15, exceeding the Zacks Consensus Estimate by 1% and reflecting a year-over-year increase of 0.8% [1] - The company's GAAP EPS was $3.98, marking a 15% increase year over year [1] - Following the earnings announcement, shares of Thermo Fisher rose 1.7% in pre-market trading [2] Revenue Performance - Total revenues for the quarter reached $10.36 billion, a 0.2% increase year over year, surpassing the Zacks Consensus Estimate by 1.1% [3] - Organic revenues increased by 1% year over year [3] Segment Analysis - Life Sciences Solutions segment (22.6% of total revenues) saw revenues increase by 2.4% year over year to $2.34 billion, exceeding estimates [4] - Analytical Instruments segment (16.6%) reported a 1.8% year-over-year increase in revenues to $1.72 billion, which fell short of estimates [5] - Specialty Diagnostics segment (11.1%) experienced a 3.5% year-over-year revenue increase to $1.15 billion, surpassing predictions [6] - Laboratory Products and Biopharma Services segment (54.4%) saw a decline of 1.4% year over year, with revenues at $5.64 billion, slightly below estimates [7] Margin Performance - Gross margin for the first quarter was 41.6%, contracting by 5 basis points year over year due to a 0.3% rise in the cost of revenues [8] - Selling, general and administrative expenses decreased by 0.6% to $1.72 billion, while research and development expenses increased by 3.3% to $342 million [8] - Adjusted operating margin was 21.7%, reflecting a contraction of 2 basis points [8] Financial Position - At the end of Q1 2025, cash and cash equivalents and short-term investments totaled $5.95 billion, up from $5.57 billion at the end of Q4 2024 [9] - Net cash from operating activities was $723 million, down from $1.25 billion a year ago [10] - The company has a consistent dividend-paying history, with a five-year annualized dividend growth of 15.10% [10] Strategic Developments - During the first quarter, Thermo Fisher launched several innovative products, including the Thermo Scientific Vulcan Automated Lab and Olink Reveal proteomics kits, contributing to commercial success [12] - The company announced an agreement to acquire Solventum's Purification & Filtration Business for $4.1 billion in cash [12] Overall Assessment - Thermo Fisher's first-quarter results exceeded expectations in terms of earnings and revenues, with growth in most segments except for Laboratory Products and Biopharma Services [11] - The contraction in margins was noted as a concern, and the company is expected to provide guidance for 2025 in an upcoming earnings call [11]

Core Viewpoint - Boston Scientific Corporation (BSX) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of 75 cents, a 33.9% increase year-over-year, surpassing both the Zacks Consensus Estimate and the company's own guidance range [1][3][11] Financial Performance - The first-quarter revenue reached $4.66 billion, reflecting a 20.9% year-over-year increase on a reported basis and 22.2% on an operational basis, exceeding the Zacks Consensus Estimate by 2.3% [3][11] - Reported EPS for the quarter was 45 cents, marking a 36.4% increase from the previous year [2] Revenue Breakdown - Revenue growth by region included a 31.1% increase in the United States, 5.5% in EMEA, 8.2% in Asia Pacific, and 4.4% in Latin America and Canada [4] - Emerging markets saw a reported revenue growth of 6.5% [4] Segment Performance - MedSurg segment revenues were $1.58 billion, up 11.7% year-over-year, with notable contributions from Endoscopy ($673 million), Urology ($633 million), and Neuromodulation ($271 million) [6] - Cardiovascular segment revenues reached $3.09 billion, a 26.2% increase, with Cardiology business sales totaling $2.43 billion, up 31.2% [7] Margin Analysis - Gross margin expanded by 19 basis points to 68.8%, while adjusted operating margin increased by 127 basis points to 24.8% [8] Future Outlook - For 2025, BSX anticipates net sales growth of approximately 15-17% on a reported basis and 12-14% on an organic basis, with adjusted EPS expected in the range of $2.87-$2.94 [9][10] - The second quarter of 2025 is projected to see revenue growth of 17.5-19.5% on a reported basis [10] Strategic Developments - Recent acquisitions include SoniVie Ltd. and Bolt Medical, which are expected to positively impact the company's growth trajectory [12]

Core Viewpoint - Concentra Group Holding Parent, Inc. has announced a definitive agreement to acquire Pivot Onsite Innovations, enhancing its position in the onsite healthcare market [1][2][4]. Company Summary - The acquisition of Pivot Onsite Innovations will expand Concentra's network to approximately 350 clinics across more than 40 states, significantly increasing its service capabilities in onsite healthcare [7][9]. - The deal is valued at $55 million, with funding sourced from available cash and an existing revolving credit facility, and is expected to close in the second quarter of 2025 [10]. - Concentra currently has a market capitalization of $2.6 billion and anticipates earnings growth of 7.5% over the next five years [5]. Industry Summary - The onsite healthcare market is experiencing growing demand as employers prioritize immediate and accessible care within the workplace, which supports employee wellness and occupational health programs [7][11]. - The global occupational health market is projected to grow from $5.45 billion in 2025 to $8.47 billion by 2032, reflecting a compound annual growth rate (CAGR) of 6.5% [11].

Core Viewpoint - Quest Diagnostics Inc. reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of $2.21, exceeding estimates and showing year-over-year growth [1][2][8] Financial Performance - Adjusted EPS of $2.21 beat the Zacks Consensus Estimate by 2.8% and increased by 8.3% compared to the previous year [1] - GAAP EPS was $1.94, reflecting a 12.8% increase from the same quarter last year [2] - Revenues rose 12.1% year over year to $2.65 billion, surpassing the Zacks Consensus Estimate by 1.5% [3] - Diagnostic Information Services revenues increased by 12.7% year over year to $2.59 billion, exceeding projections [3] - Volumes measured by requisitions were up 12.5% year over year, with revenue per requisition increasing by 0.3% [4] Margin and Cost Analysis - Cost of services was $1.79 billion, up 12.2% year over year, while gross profit reached $863 million, an 11.9% increase [5] - Gross margin stood at 32.5%, nearly unchanged from the previous year [5] - SG&A expenses were $476 million, an 8.1% increase from the first quarter of 2024 [5] - Adjusted operating margin improved by 60 basis points year over year to 14.6% [5] Liquidity and Financial Health - Cash and cash equivalents at the end of Q1 2025 were $188 million, down from $549 million at the end of Q4 2024 [6] - Cumulative net cash from operating activities was $314 million, compared to $154 million at the same time last year [6] - The company has a five-year annualized dividend growth rate of 7.17% [6] 2025 Guidance - Full-year 2025 revenue outlook is reaffirmed at $10.70 billion to $10.85 billion, indicating a year-over-year increase of 8.4% to 9.9% [7] - Adjusted EPS guidance remains unchanged at $9.55 to $9.80, with the Zacks Consensus Estimate at $9.68 [7] Market Reaction and Outlook - Following the earnings report, DGX shares gained nearly 6.7% in pre-market trading [2] - The growth in revenue was attributed to a rebound in demand, contributions from acquisitions, and expanded health plan access [8][9]

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report first-quarter 2025 results on May 5, before market open.In the last reported quarter, the company’s earnings of $2.31 surpassed the Zacks Consensus Estimate by 0.4%. ZBH beat on earnings in three of the trailing four quarters and missed on one occasion, the average earnings surprise being 1.28%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).Q1 Estimates for ZBHThe Zacks Consensus Estimate for revenues is pegged at $1.89 bil ...